Bavarian Nordic Receives European Approval of Extension of Vaccine Label to Include Monkeypox

COPENHAGEN, Denmark, July 25, 2022 – Bavarian Nordic A/S (OMX:BAVA) announced today that the European Commission (EC) has extended the marketing authorization for the Company’s smallpox vaccine, IMVANEX^® to include protection from monkeypox and disease caused by vaccinia virus. The approval, which follows a positive opinion by the Committee for Medicinal Products for Human Use (CHMP) on July 22, 2022, is valid in all European Union Member States as well as in Iceland, Liechtenstein, and Norway.